Anthracycline
Female sex not linked to HF after treatment with anthracyclines
HF from cardiotoxic breast cancer therapies may confer better prognosis vs. other causes
Women who developed HF following cardiotoxic breast cancer treatment had fewer comorbidities and better overall 5-year prognosis compared with women who developed HF for other reasons, researchers reported.
Statins may lower cardiotoxic effect of anthracyclines in early breast cancer treatment
Older women who received early breast cancer treatment with anthracycline experienced fewer HF hospitalizations associated with the cardiotoxic effects of chemotherapy when also exposed to statin therapy, researchers reported.
VIDEO: Use of carboplatin-taxane effective, less toxic in certain breast cancers
In this video, Marisa C. Weiss, MD, director of breast radiation oncology at Lankenau Medical Center and Breastcancer.org chief medical officer, discusses presentations in breast cancer from the ASCO 2020 Virtual Meeting.
Anthracycline chemotherapy shows no benefit in HER2-positive breast cancer
Anthracyclines did not improve 3-year efficacy as part of a neoadjuvant chemotherapy regimen for patients with HER2-positive breast cancer, according to results of the TRAIN-2 study presented during the ASCO20 Virtual Scientific Program.
Dexrazoxane may reduce cardiotoxicity from breast cancer treatment
Dexrazoxane reduced the risk for cardiac events and clinical heart failure among women with breast cancer who underwent anthracycline chemotherapy, according to results of a systematic review and meta-analysis published in JACC: Cardio-Oncology.
Collaboration between cardiologists, oncologists may improve CV outcomes during, after cancer treatment
SAN ANTONIO — There continues to be an unmet need regarding CVD prevention in patients who are currently receiving cancer treatment or are cancer survivors, although partnership with cardiology and oncology may help improve outcomes, according to a presentation at the American Society for Preventive Cardiology Congress on CVD Prevention.
The dangers of QTc interval prolongation and medications used for cancer treatment
The QT interval is an electrocardiogram representation of ventricular depolarization and repolarization. It is measured from the start of the QRS complex until the T wave termination on ECG. Because heart rate can affect the QT interval — the QT interval lengthens with bradycardia and shortens with tachycardia — it is recommended to calculate a corrected QT interval.